Hans‐Jürgen Biersack

Outcome of peptide receptor radionuclide therapy with 177Lu-octreotate in advanced grade 1/2 pancreatic neuroendocrine tumours

Samer Ezziddin, Feras Khalaf, Maria Vanezi et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2014 · 185 citations

Pancreatic Cancer, Medicine, Radionuclide Therapy +9

Predictors of Long-Term Outcome in Patients with Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors After Peptide Receptor Radionuclide Therapy with ¹⁷⁷Lu-Octreotate

Samer Ezziddin, Mared Attassi, Charlotte J. Yong‐Hing et al. · Journal of Nuclear Medicine · 2014 · 184 citations · Full text

Long-Term Hematotoxicity After Peptide Receptor Radionuclide Therapy with ¹⁷⁷Lu-Octreotate

Amir Sabet, Khaled Ezziddin, Ulrich‐Frank Pape et al. · Journal of Nuclear Medicine · 2013 · 164 citations · Full text

Repeated Bone-Targeted Therapy for Hormone-Refractory Prostate Carcinoma: Randomized Phase II Trial With the New, High-Energy Radiopharmaceutical Rhenium-188 Hydroxyethylidenediphosphonate

H. Palmedo, Agnieska Manka-Waluch, Peter Albers et al. · Journal of Clinical Oncology · 2003 · 158 citations

Technetium-99m-MIBI scintimammography for suspicious breast lesions.

H. Palmedo, A. Schomburg, Frank Grünwald et al. · PubMed · 1996 · 138 citations